NCT01525082 2024-02-06Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStanford UniversityPhase 2 Completed20 enrolled 15 charts
NCT01010126 2019-01-25Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerNational Cancer Institute (NCI)Phase 2 Completed252 enrolled 20 charts